Danshen (Salvia miltiorhiza) inhibits Leu27 IGF-II-induced hypertrophy in H9c2 cells.
Animals
Calcineurin
/ metabolism
Cardiomegaly
/ prevention & control
Cell Enlargement
/ drug effects
Cell Line
Cell Survival
/ drug effects
Drugs, Chinese Herbal
/ isolation & purification
Estrogen Receptor Antagonists
/ pharmacology
Fulvestrant
/ pharmacology
Insulin-Like Growth Factor II
/ analogs & derivatives
Myoblasts, Cardiac
/ drug effects
Protein Transport
Rats
Receptor, IGF Type 2
/ metabolism
Receptors, Estrogen
/ metabolism
Salvia miltiorrhiza
/ chemistry
Signal Transduction
Danshen
ER
IGFIIR
NFAT3
cardiac hypertrophy
Journal
Environmental toxicology
ISSN: 1522-7278
Titre abrégé: Environ Toxicol
Pays: United States
ID NLM: 100885357
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
14
02
2020
revised:
11
04
2020
accepted:
22
04
2020
pubmed:
18
5
2020
medline:
9
10
2020
entrez:
17
5
2020
Statut:
ppublish
Résumé
In this study, we used ICI 182 780 (ICI), an estrogen receptor (ER) antagonist, to investigate the estrogenic activity of Danshen, and to further explored whether Danshen extract can block Leu27IGF-II-induced hypertrophy in H9c2 cardiomyoblast cells. We first used an IGF-II analog Leu27IGF-II, which specifically activates IGF2R signaling cascades and induces H9c2 cardiomyoblast cell hypertrophy. However, Danshen extract completely inhibited Leu27IGF-II-induced cell size increase, ANP and BNP hypertrophic marker expression, and IGF2R induction. We also observed that Danshen extract inhibited calcineurin protein expression and NFAT3 nuclear translocation, leading to suppression of Leu27IGF-II-induced cardiac hypertrophy. Moreover, the anti-Leu27IGF-II-IGF2R signaling effect of Danshen was totally reversed by ICI, which suggest the cardio protective effect of Danshen is mediated through estrogen receptors. Our study suggests that, Danshen exerts estrogenic activity, and thus, it could be used as a selective ER modulator in IGFIIR induced hypertrophy model.
Substances chimiques
Drugs, Chinese Herbal
0
Estrogen Receptor Antagonists
0
Receptor, IGF Type 2
0
Receptors, Estrogen
0
insulin-like growth factor II, Leu(27)-
132729-29-4
dan-shen root extract
1693AM5SBN
Fulvestrant
22X328QOC4
Insulin-Like Growth Factor II
67763-97-7
Calcineurin
EC 3.1.3.16
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1043-1049Subventions
Organisme : Asia & China Medical University Hospital
ID : ASIA-106-CMUH-01
Organisme : China Medical University Hospital and Asia University
ID : CMU105-ASIA-04
Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749-770.
Lee H, Han K, Park JB, et al. Risk of end-stage renal disease in patients with hypertrophic cardiomyopathy: a nationwide population-based cohort study. Sci Rep. 2019;9(1):14565.
Heo D, Lim S, Lee J, et al. Radiological assessment of effectiveness of soluble RAGE in attenuating angiotensin II-induced LVH mouse model using in vivo 9.4T MRI. Sci Rep. 2019;9(1):8475.
Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. Circulation. 1995;92(4):785-789.
Cambronero F, Marin F, Roldan V, Hernandez-Romero D, Valdes M, Lip GY. Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur Heart J. 2009;30(2):139-151.
Lin D, Bobkova A, Homsher E, Tobacman LS. Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy. J Clin Invest. 1996;97(12):2842-2848.
Elliott K, Watkins H, Redwood CS. Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J Biol Chem. 2000;275(29):22069-22074.
Crilley JG, Boehm EA, Blair E, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41(10):1776-1782.
Frey N, McKinsey TA, Olson EN. Decoding calcium signals involved in cardiac growth and function. Nat Med. 2000;6(11):1221-1227.
Molkentin JD. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res. 2004;63(3):467-475.
Taigen T, De Windt LJ, Lim HW, Molkentin JD. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. 2000;97(3):1196-1201.
De Windt LJ, Lim HW, Bueno OF, et al. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2001;98(6):3322-3327.
Chu CH, Tzang BS, Chen LM, et al. IGF-II/mannose-6-phosphate receptor signaling induced cell hypertrophy and atrial natriuretic peptide/BNP expression via Galphaq interaction and protein kinase C-alpha/CaMKII activation in H9c2 cardiomyoblast cells. J Endocrinol. 2008;197(2):381-390.
Weng YS, Wang HF, Pai PY, et al. Tanshinone IIA prevents Leu27IGF-II-induced cardiomyocyte hypertrophy mediated by estrogen receptor and subsequent Akt activation. Am J Chin Med. 2015;43(8):1567-1591.
Huang CY, Kuo WW, Yeh YL, et al. ANG II promotes IGF-IIR expression and cardiomyocyte apoptosis by inhibiting HSF1 via JNK activation and SIRT1 degradation. Cell Death Differ. 2014;21(8):1262-1274.
Chu CH, Huang CY, Lu MC, et al. Enhancement of AG1024-induced H9c2 cardiomyoblast cell apoptosis via the interaction of IGF2R with Galpha proteins and its downstream PKA and PLC-beta modulators by IGF-II. Chin J Physiol. 2009;52(1):31-37.
Chen RJ, Wu HC, Chang MH, et al. Leu27IGF2 plays an opposite role to IGF1 to induce H9c2 cardiomyoblast cell apoptosis via Galphaq signaling. J Mol Endocrinol. 2009;43(6):221-230.
Li ZM, Xu SW, Liu PQ. Salvia miltiorrhiza Burge (Danshen): a golden herbal medicine in cardiovascular therapeutics. Acta Pharmacol Sin. 2018;39(5):802-824.
Yuan T, Chen Y, Zhou X, Lin X, Zhang Q. Effectiveness and safety of Danshen injection on heart failure: protocol for a systematic review and meta-analysis. Medicine. 2019;98(22):e15636.
Liu B, Du Y, Cong L, Jia X, Yang G. Danshen (Salvia miltiorrhiza) compounds improve the biochemical indices of the patients with coronary heart disease. Evid-Based Compl Alter Med: eCAM. 2016;2016:9781715.
Han S, Zheng Z, Ren D. Effect of Salvia miltiorrhiza on left ventricular hypertrophy and cardiac aldosterone in spontaneously hypertensive rats. J Huazhong Univ Sci Technolog Med Sci. 2002;22(4):302-304.
Wang L, Yu J, Fordjour PA, et al. Danshen injection prevents heart failure by attenuating post-infarct remodeling. J Ethnopharmacol. 2017;205:22-32.
Ren J, Fu L, Nile SH, Zhang J, Kai G. Salvia miltiorrhiza in treating cardiovascular diseases: a review on its pharmacological and clinical applications. Front Pharmacol. 2019;10:753.
Tan X, Li J, Wang X, et al. Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/NFATc3 pathway. Int J Biol Sci. 2011;7(3):383-389.
Beukers MW, Oh Y, Zhang H, Ling N, Rosenfeld RG. [Leu27] insulin-like growth factor II is highly selective for the type-II IGF receptor in binding, cross-linking and thymidine incorporation experiments. Endocrinology. 1991;128(2):1201-1203.
Lee H-P, Chen P-C, Wang S-W, et al. Plumbagin suppresses endothelial progenitor cell-related angiogenesis in vitro and in vivo. J Funct Foods. 2019;52:537-544.
Liu S-C, Tsai C-H, Wu T-Y, et al. Soya-cerebroside reduces IL-1β-induced MMP-1 production in chondrocytes and inhibits cartilage degradation: implications for the treatment of osteoarthritis. Food Agric Immunol. 2019;30(1):620-632.
Lin CC, Chen KB, Tsai CH, et al. Casticin inhibits human prostate cancer DU 145 cell migration and invasion via Ras/Akt/NF-kappaB signaling pathways. J Food Biochem. 2019;43(7):e12902.
Wei Y, Li J, Huang J, et al. Elevation of IGF-2 receptor and the possible underlying implications in end-stage heart failure patients before and after heart transplantation. J Cell Mol Med. 2012;16(5):1038-1046.
Wang KC, Brooks DA, Thornburg KL, Morrison JL. Activation of IGF-2R stimulates cardiomyocyte hypertrophy in the late gestation sheep fetus. J Physiol. 2012;590(21):5425-5437.
Weng YS, Kuo WW, Lin YM, et al. Danshen mediates through estrogen receptors to activate Akt and inhibit apoptosis effect of Leu27IGF-II-induced IGF-II receptor signaling activation in cardiomyoblasts. Food Chem Toxicol: Int J Publ Br Indus Biol Res Assoc. 2013;56:28-39.
Chen YF, Lee NH, Pai PY, et al. Tanshinone-induced ERs suppresses IGFII activation to alleviate Ang II-mediated cardiac hypertrophy. J Recept Signal Transduct Res. 2017;37(5):493-499.
Pedram A, Razandi M, Aitkenhead M, Levin ER. Estrogen inhibits cardiomyocyte hypertrophy in vitro. Antagonism of calcineurin-related hypertrophy through induction of MCIP1. J Biol Chem. 2005;280(28):26339-26348.
Pedram A, Razandi M, Lubahn D, Liu J, Vannan M, Levin ER. Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin. Endocrinology. 2008;149(7):3361-3369.
Dolmetsch RE, Lewis RS, Goodnow CC, Healy JI. Differential activation of transcription factors induced by Ca2+ response amplitude and duration. Nature. 1997;386(6627):855-858.
Crabtree GR. Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. Cell. 1999;96(5):611-614.
Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93(2):215-228.
Dukhanin AS, Khankoeva AI. Experimental approaches to determining molecular mechanisms of antiarrhythmic and cardioprotective actions of new compounds. Vestn Ross Akad Med Nauk. 1999;(3):7-15.
Zou Y, Hiroi Y, Uozumi H, et al. Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation. 2001;104(1):97-101.
Rothermel BA, McKinsey TA, Vega RB, et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2001;98(6):3328-3333.
Wilkins BJ, De Windt LJ, Bueno OF, et al. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol. 2002;22(21):7603-7613.
vanRooij E, Doevendans PA, deTheije CC, Babiker FA, Molkentin JD, deWindt LJ. Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy. J Biol Chem. 2002;277(50):48617-48626.